Géraldine Daneau

Géraldine Daneau

Auto-generated profile, based on publicly available information

Géraldine Daneau

Affiliation Immunology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
PDPapa Alassane Diaw
Papa Alassane Diaw
GDGéraldine Daneau
Géraldine Daneau
ACAbdoul Aziz Coly
Abdoul Aziz Coly
BNBirahim Pierre Ndiaye
Birahim Pierre Ndiaye
DWDjibril Wade
Djibril Wade
TDTandakha Ndiaye Dieye
Tandakha Ndiaye Dieye
BACKGROUND: CD4(+) T-cell enumeration (CD4 count) is used as a criterion to initiate antiretroviral therapy (ART) in HIV patients and to monitor treatment efficacy. However, simple, affordable, and reliable point-of-care (POC) instruments adapted to resource-limited settings are still lacking. The PIMA CD4 analyzer is a new POC instrument for CD4 counting that uses disposable cartridges and a battery-powered analyzer. METHODS: Whole blood samples were taken by venipuncture or by finger prick from 300 subjects, including HIV-infected patients and HIV (-) controls. CD4 counts were measured by PIMA (using venous or capillary blood) and by FACSCount (using venous blood) considered as the reference. RESULTS: Similar CD4 counts were obtained by PIMA and FACSCount using either HIV+ venous blood or HIV+ finger-prick blood samples. However, with a concordance coefficient of 0.88 and a Pearson correlation of 0.89, finger-prick blood performed not as good as venous blood (0.97 and 0.98, respectively). For a clinical decision to start ART at 200 CD4 cells per microliter, sensitivity of PIMA was 90%/91% and specificity 98%/96% for venous/finger-prick blood, respectively, and for a treatment threshold of 350 CD4 cells per microliter, the sensitivity was 98%/91% and the specificity was 79%/80% for venous/finger-prick blood, respectively. Repeatability (precision) on venous blood resulted in a coefficient of variation of 4%. Using finger-prick blood, the average instrument error frequency resulting in aborted analyses was 14%. CONCLUSIONS: PIMA is a good POC instrument for screening adult HIV-infected patients in resource-limited settings for treatment eligibility. Its performance on finger-prick blood is not as good as on venous blood. Adequate training for correct use of finger-prick blood samples is mandatory

9 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMichèle Bergeron
Michèle Bergeron
GDGéraldine Daneau
Géraldine Daneau
TDTao Ding
Tao Ding
NSNadia E Sitoe
Nadia E Sitoe
LWLarry E Westerman
Larry E Westerman
TPTrevor F Peter
Trevor F Peter
Point-of-care (POC) CD4 testing can improve access to treatment by enabling decentralization and reducing patient loss-to-follow-up. As new POC CD4 technologies become available, their performance should be assessed before widespread deployment. This study reports the findings of five independent evaluations of the PointCare NOW CD4 system. Evaluations were conducted in Southern Africa (Mozambique, South Africa) and North America (Canada, USA). 492 blood samples (55 from HIV-negative blood donors and 437 from HIV-infected patients, including 20 children aged between 12 and 59 months) were tested with both the PointCare NOW and reference flow cytometry instruments. Assessment of bias, precision and levels of clinical misclassification for absolute and percent CD4 count was conducted. PointCare NOW significantly overestimated CD4 absolute counts with a mean relative bias of +35.0%. Bias was greater in samples with CD4 counts below ≤350cells/µl (+51.3%) than in the CD4 >350cells/µl stratum (15.1%). Bias in CD4% had a similar trend with an overall relative mean bias of +25.6% and a larger bias for low CD4 stratum (+40.2%) than the higher CD4 stratum (+5.8%). Relative bias for CD4% in children was −6.8%. In terms of repeatability, PointCare NOW had a coefficient of variation of 11%. Using a threshold of 350cells/µl, only 47% of patients who qualified for antiretroviral therapy with reference CD4 testing, would have been eligible for treatment with PointCare NOW test results. This was 39% using a 200cells/µl threshold. Agreement with infant samples was higher, with 90% qualifying at a 25% eligibility threshold. The performance of the PointCare NOW instrument for absolute and percent CD4 enumeration was inadequate for HIV clinical management in adults. In children, the small sample size was not large enough to draw a conclusion. This study also highlights the importance of independent evaluation of new diagnostic technology platforms before deployment.

29 July 2011 in Journal of Immunological Methods
Verified
Journal Article
Closed access
TDTandakha Ndiaye Dieye
Tandakha Ndiaye Dieye
PDPapa Alassane Diaw
Papa Alassane Diaw
GDGéraldine Daneau
Géraldine Daneau
DWDjibril Wade
Djibril Wade
MNMaguette Sylla Niang
Maguette Sylla Niang
SMSouleymane Mboup
Souleymane Mboup

24 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GDGéraldine Daneau
Géraldine Daneau
NGNatasha Gous
Natasha Gous
LSLesley Scott
Lesley Scott
JPJoachim Potgieter
Joachim Potgieter
LKLuc Kestens
Luc Kestens
WSWendy Stevens
Wendy Stevens
HIV-infected patients require antiretroviral treatment for life. To improve access to care, CD4 enumeration and viral load tests have been redesigned to be used as point-of-care techniques using finger-stick blood. Accurate CD4 counting in capillary blood requires a free flowing blood drop that is achieved by blade incision. The aim of this study was to assess the attitude of the patients toward blade-based finger-stick blood donation. Four hundred and ninety-nine patients were included (299 patients from South Africa and 200 from Belgium). They completed a questionnaire to express their preference for finger stick or venipuncture, after undergoing both. The South African patient cohort was divided in two groups, receiving either single or multiple finger stick for CD4 and other HIV-related tests. The Belgian patients received a single finger stick for CD4 testing, and were asked to respond directly and again after two days. The majority of the patients preferred the finger stick to the venipuncture. The perceived pain using the blade was superior to a small needle, but similar to a large needle. They preferred up to three finger sticks over one venipuncture. Up to 30% of the patients changed their mind over two days. The main reason for choosing a finger stick was continued bleeding after venipuncture. The most cited objection to finger stick was pain/soreness. Patient perceptions support the implementation of donating capillary blood with blade-based finger stick during CD4 point-of-care testing.

22 March 2016 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
GDGéraldine Daneau
Géraldine Daneau
JBJozefien Buyze
Jozefien Buyze
DWDjibril Wade
Djibril Wade
PDPapa Alassane Diaw
Papa Alassane Diaw
TDTandakha Ndeye Dieye
Tandakha Ndeye Dieye
LKLuc Kestens
Luc Kestens

27 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GDGéraldine Daneau
Géraldine Daneau
SASaid Aboud
Said Aboud
IPIrena Prat
Irena Prat
WUWilly Urassa
Willy Urassa
LKLuc Kestens
Luc Kestens
CD4 T-cell counts are widely used to assess treatment eligibility and to follow-up HIV-infected patients. The World Health Organization prequalification of in vitro diagnostics program conducted a performance evaluation of the FACSPresto (BD Biosciences), a new point-of-care instrument to measure absolute CD4-T cell (CD4) counts and percentages in venous and capillary blood samples from HIV-infected patients. Patients were recruited in Belgium (200 patients) and in Tanzania (247 patients). Venous blood samples were analyzed in two nearby reference laboratories. In addition, nurses/technicians collected a capillary blood sample by finger prick directly into a FACSPresto CD4 cartridge. Assay precision was assessed on fresh blood and on external quality control samples. Trueness (bias) was assessed by comparing results from FACSPresto with the reference (single-platform FACSCalibur). Clinical misclassification was measured at 200, 350 and 500 cells/μL thresholds. Intra-assay precision was < 6%, and inter-assay < 8%. CD4 results from FACSPresto and reference method resulted in regression slopes of 0.99–1.11 using either venous or capillary blood. Correlation was better for venous than for capillary blood (minimum 0.97 vs 0.93 respectively). Capillary blood resulted in a larger bias than venous blood, with 24 and 83 cells/μL for absolute CD4 counts on capillary blood in Antwerp and Dar es Salaam respectively, vs 12 and 41 cells/μL on venous blood. Bias on CD4% was < 1% on both venous and capillary blood, and was proportionally better than for absolute CD4 counts. Clinical misclassification was in line with the average overestimation, showing a very good specificity, but sensitivity around 70–90%. The rejection rate was 11% on first reading, leading to 6% of all samples without final result after a second reading. The FACSPresto performed very well on venous blood samples, and well on capillary blood samples.